Growth Metrics

Neogenomics (NEO) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$27.1 million.

  • Neogenomics' Income towards Parent Company fell 53.28% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 45.98%. This contributed to the annual value of -$78.7 million for FY2024, which is 10.51% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Income towards Parent Company is -$27.1 million, which was up 39.84% from -$45.1 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Income towards Parent Company ranged from a high of $75.9 million in Q2 2021 and a low of -$49.4 million during Q1 2022.
  • Its 3-year average for Income towards Parent Company is -$24.1 million, with a median of -$24.3 million in 2023.
  • Examining YoY changes over the last 5 years, Neogenomics' Income towards Parent Company showed a top increase of 1,211.86% in 2021 and a maximum decrease of 895.78% in 2021.
  • Over the past 5 years, Neogenomics' Income towards Parent Company (Quarterly) stood at -$41.8 million in 2021, then surged by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then fell by 6.97% to -$15.3 million in 2024, then slumped by 53.28% to -$27.1 million in 2025.
  • Its Income towards Parent Company was -$27.1 million in Q3 2025, compared to -$45.1 million in Q2 2025 and -$25.9 million in Q1 2025.